ProfessionalDiscontinued

Charles S. Grob, M.D, endorses Healthcare Practitioner Access to Psilocybin for Professional Training

This page presents TheraPsil’s case for allowing healthcare professionals approved to conduct psychedelic treatment to have first-hand psilocybin experience as part of professional training. It includes a letter of support from Charles S. Grob, M.D. and background on TheraPsil’s training efforts.

Provider

Therapsil

English

Schedule

30 years

Enrollment

Price on request

Decision Summary

Best fit
Healthcare professionals involved in psilocybin-assisted psychotherapy, including doctors, therapists, clinical counselors, nurses, social workers, and related practitioners.
Format
Not listed
Time commitment
30 years
Credential signal
Not listed

Course Overview

TheraPsil describes a need for more qualified healthcare professionals trained in psilocybin-assisted psychotherapy. The page explains that TheraPsil has been developing a training program that combines lectures, case studies, readings, discussions, and experiential learning. The featured material is a letter of support from Charles S. Grob, M.D., who argues that therapists who will guide psychedelic treatment may benefit from personal experience with psychedelics in order to better support patients and maintain safety. The content is intended for healthcare professionals, therapists, clinical counselors, nurses, social workers, and others involved in psilocybin-assisted psychotherapy or professional training related to psychedelic treatment.

Who is this for?

Healthcare professionals involved in psilocybin-assisted psychotherapy, including doctors, therapists, clinical counselors, nurses, social workers, and related practitioners.

Prerequisites

None stated on the page.

About the Provider

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

View all Therapsil courses

Course FAQ

Who is this course for?

Healthcare professionals involved in psilocybin-assisted psychotherapy, including doctors, therapists, clinical counselors, nurses, social workers, and related practitioners.

Are there prerequisites?

None stated on the page.

What is the format and time commitment?

Time commitment: 30 years.

How much does it cost?

This listing does not have a public price yet. Check [object Object] for current tuition, fees, or application-based pricing.

Is this course currently available?

The current listing status is Discontinued. Use the provider website for the latest enrollment status.

Related Courses

View all courses